Literature DB >> 26800972

Phosphate binders in chronic kidney disease: a systematic review of recent data.

Jürgen Floege1.   

Abstract

Hyperphosphatemia is common in chronic kidney disease (CKD) and is treated by dietary measures, dialysis techniques and/or phosphate binders. For the present review PubMed was searched for new publications on phosphate binders appearing between January 2010 and October 2015. This review summarizes the latest information on non-pharmacological measures and their problems in lowering phosphate in CKD patients, effects of phosphate binders on morbidity and mortality, adherence to phosphate binder therapy as well as new information on specific aspects of the various phosphate binders on the market: calcium acetate, calcium carbonate, magnesium-containing phosphate binders, polymeric phosphate binders (sevelamer, bixalomer, colestilan), lanthanum carbonate, ferric citrate, sucroferric oxyhydroxide, aluminum-containing phosphate binders, and new compounds in development. The review also briefly covers the emerging field of drugs targeting intestinal phosphate transporters.

Entities:  

Keywords:  Adherence; CKD; Phosphate binder; Phosphate transport

Mesh：

Substances：

Year:  2016        PMID： 26800972     DOI： 10.1007/s40620-016-0266-9

Source DB:  PubMed          Journal:  J Nephrol        ISSN： 1121-8428            Impact factor:   3.902


  119 in total

1.  Nurse-led education and counselling to enhance adherence to phosphate binders.

Authors:  Yoleen P Van Camp; Sofie A Huybrechts; Bart Van Rompaey; Monique M Elseviers
Journal:  J Clin Nurs       Date:  2011-12-09       Impact factor: 3.036

2.  Randomized, Double-Blind, Placebo-Controlled, Withdrawal Study of Colestilan after Dose Titration in Chronic Kidney Disease Dialysis Patients with Hyperphosphatemia.

Authors:  Joachim Hertel; Francesco Locatelli; Goce Spasovski; Nada Dimkovic; Christoph Wanner
Journal:  Nephron       Date:  2015-07-10       Impact factor: 2.847

3.  A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.

Authors:  Geoffrey A Block; Steven Fishbane; Mariano Rodriguez; Gerard Smits; Shay Shemesh; Pablo E Pergola; Myles Wolf; Glenn M Chertow
Journal:  Am J Kidney Dis       Date:  2014-11-04       Impact factor: 8.860

Review 4.  The use of fibroblast growth factor 23 testing in patients with kidney disease.

Authors:  Edward R Smith
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 8.237

Review 5.  Phosphate: an old bone molecule but new cardiovascular risk factor.

Authors:  Navid Shobeiri; Michael A Adams; Rachel M Holden
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

Review 6.  Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients.

Authors:  Francesco Locatelli; Nada Dimkovic; Goce Spasovski
Journal:  Expert Opin Pharmacother       Date:  2014-07       Impact factor: 3.889

7.  Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.

Authors:  Yuki Takahara; Yoshimi Matsuda; Shunichi Takahashi; Takashi Shigematsu
Journal:  Clin Nephrol       Date:  2014-09       Impact factor: 0.975

8.  Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.

Authors:  Jürgen Floege; Adrian C Covic; Markus Ketteler; Johannes F E Mann; Anjay Rastogi; Bruce Spinowitz; Edward M F Chong; Sylvain Gaillard; Laura J Lisk; Stuart M Sprague
Journal:  Nephrol Dial Transplant       Date:  2015-02-16       Impact factor: 5.992

9.  Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia.

Authors:  Tineke M De Schutter; Geert J Behets; Hilde Geryl; Mirjam E Peter; Sonja Steppan; Kristina Gundlach; Jutta Passlick-Deetjen; Patrick C D'Haese; Ellen Neven
Journal:  Kidney Int       Date:  2013-03-13       Impact factor: 10.612

10.  Possibility of lanthanum absorption in the stomach.

Authors:  Akiko Tonooka; Susumu Uda; Hiroki Tanaka; Atsushi Yao; Toshimasa Uekusa
Journal:  Clin Kidney J       Date:  2015-07-16
View more
  21 in total

1.  Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3-4 chronic kidney disease.

Authors:  Ying Gao; Guiyun Wang; Yang Li; Chenxiao Lv; Zunsong Wang
Journal:  J Nephrol       Date:  2018-12-26       Impact factor: 3.902

2.  Lowering Expectations with Niacin Treatment for CKD-MBD.

Authors:  Tilman B Drüeke; Ziad A Massy
Journal:  Clin J Am Soc Nephrol       Date:  2017-12-05       Impact factor: 8.237

3.  Predictors of first ischemic lower limb ulcer in dialysis patients: an observational cohort study.

Authors:  Simeone Andrulli; Chiara Chiavenna; Maria Carla Bigi; Monica Crepaldi; Cesare Dell'Oro; Flavia Tentori; Celestina Manzoni; Giuseppe Bacchini; Mauro Maria Corti; Giuseppe Pontoriero
Journal:  J Nephrol       Date:  2017-08-22       Impact factor: 3.902

4.  Admission hyperphosphatemia increases the risk of acute kidney injury in hospitalized patients.

Authors:  Charat Thongprayoon; Wisit Cheungpasitporn; Michael A Mao; Ankit Sakhuja; Stephen B Erickson
Journal:  J Nephrol       Date:  2017-10-03       Impact factor: 3.902

Review 5.  The role of calcium supplementation in healthy musculoskeletal ageing : An expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF).

Authors:  N C Harvey; E Biver; J-M Kaufman; J Bauer; J Branco; M L Brandi; O Bruyère; V Coxam; A Cruz-Jentoft; E Czerwinski; H Dimai; P Fardellone; F Landi; J-Y Reginster; B Dawson-Hughes; J A Kanis; R Rizzoli; C Cooper
Journal:  Osteoporos Int       Date:  2016-10-20       Impact factor: 4.507

6.  High-Iron Consumption Impairs Growth and Causes Copper-Deficiency Anemia in Weanling Sprague-Dawley Rats.

Authors:  Jung-Heun Ha; Caglar Doguer; Xiaoyu Wang; Shireen R Flores; James F Collins
Journal:  PLoS One       Date:  2016-08-18       Impact factor: 3.240

7.  Lanthanum carbonate oral powder: satisfaction, preference and adherence in French and Spanish patients with end-stage renal disease.

Authors:  Michael Keith; Patricia de Sequera; François Clair; Riccardo Pedersini
Journal:  Drugs Context       Date:  2016-10-14

8.  Colonic Mucosal Ulceration and Gastrointestinal Bleeding Associated with Sevelamer Crystal Deposition in a Patient with End Stage Renal Disease.

Authors:  Sudheer Nambiar; Unnikrishnan Kunjan Pillai; Joe Devasahayam; Tony Oliver; Asha Karippot
Journal:  Case Rep Nephrol       Date:  2018-02-28

9.  Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia.

Authors:  Takashi Shigematsu; Yotaro Une; Kazuaki Ikejiri; Hironori Kanda; Masafumi Fukagawa; Tadao Akizawa
Journal:  Am J Nephrol       Date:  2021-06-07       Impact factor: 3.754

10.  Gastrointestinal complications induced by sevelamer crystals.

Authors:  Claudia Yuste; Evangelina Mérida; Eduardo Hernández; Ana García-Santiago; Yolanda Rodríguez; Teresa Muñoz; Gonzalo Jesús Gómez; Ángel Sevillano; Manuel Praga
Journal:  Clin Kidney J       Date:  2017-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.